Rights Issue for PCI Biotech

January 20, 2017

Beringer Finance has acted as sole manager in a fully underwritten rights issue for PCI Biotech, raising gross proceeds of NOK 70m.

About PCI Biotech
PCI Biotech is a cancer focused biopharmaceutical company developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities. PCI Biotech is listed at Oslo Børs.

See more of our deals here.

About us:
Beringer Finance has more than 100 years of experience as a trusted advisor within Corporate Finance and Capital Markets. We offer in-depth industry and transaction knowledge, focusing on creating long-term value for our clients in all phases of their growth and transition. Over the past 20 years Beringer Finance has completed more than 300 projects with an aggregate transaction value of more than USD 22 billion, ranging from larger cross-border transactions to smaller domestic deals. In June 2016 Beringer Finance and Fondsfinans joined forces and today has more than 80 professionals working in offices in Oslo, Stockholm, Reykjavik, Palo Alto and New York (Fondsfinans Inc).